Site-Stability Guidance Arranges Drugs Into Three Risk Groups - Revised Draft
Executive Summary
Drugs could be classified into three risk categories for the purposes of site-stability data submissions based on potential adverse effects of drug substance and product stability due to site-transfer, FDA suggests in revisions to a draft guidance.